Ongoing Study - Not Currently Enrolling

Acucela SEATTLE Study for Advanced Dry Age-Related Macular Degeneration (AMD)

Purpose of study:

This research study is being done to see how safe and effective a drug called Emixustat is in treating geographic atrophy due to the dry form of age-related macular degeneration. We want to find out whether Emixustat prevents geographic atrophy from getting worse over time.

What is Geographic Atrophy (GA)?

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for "straight-ahead" activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. The macula is located in the center of the retina, the light-sensitive tissue at the back of the eye. Geographic atrophy is an advanced form of dry macular degeneration. Currently, there is no treatment available to prevent vision loss once GA has developed.

What is involved?

Research participants will make 13 visits to the Eye Institute over the course of 2 years, where testing will be performed for the study. About 75% of the people who participate in this study will be randomly assigned to receive a dose of Emixustat and about 25% of participants will receive a placebo (a pill that contains no active drug). Participants will not be told which group they have been assigned to.


Research volunteers will receive $50 for each study visit that they complete. Reimbursement is available for mileage to and from study appointments. Taxi service to and from research appointments is also available.

You may be eligible to participate in this study if you meet these criteria.
  1. An eye doctor has told you that you have geographic atrophy from the dry form of age related macular degeneration.
  2. You are at least 55 years old.
  3. You are able to reliably administer oral medication by yourself or with help.
  4. You are not taking any of the following medications:
    • Prozac (Fluoxetine)
    • Paxil (Paroxetine)
    • Wellbutrin (Bupropion)
    • Lamisil (Terbinafine)
    • Cymbalta (Duloxetine)
    • Coumadin (Warfarin)
    • Plavix (Clopidogrel)
  5. You are willing and able to provide informed consent.
  6. You have not had a change in any of your medications or any new medications prescribed within 30 days before starting your participation in this study.
  7. You do not currently have cancer or have a history of cancer within 1 year of your participation in this study (excluding basal cell carcinoma).
  8. You have not had a heart attack or stroke within the past 6 months.

More Information:

Additional information about the SEATTLE study can be found at

IRB Approval:  PRO00019439, 5/8/2013

Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
(414) 955-8296
Directions & Maps
© 2016

Page Updated 01/05/2016